The global Depression Drugs market garnered revenue around USD 19.1 Billion in 2019 and projected to reach USD 24.3 Billion in 2027, with at a compound annual growth rate (CAGR) 2.3% throughout the estimate period from 2020 to 2027. Major depressive disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), and anxiety disorder are some of the different types of depression. Various drug classes are used to treat depression. These include Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, and tricyclic antidepressants. Rise in prevalence of depression and increase in incidence of depression among the geriatric population is boosting the global depression drugs.
North America dominated the global depression drugs market in 2019. This trend is anticipated to continue during the forecast period. Growth in awareness about the availability of new drugs to treat depression and presence of major companies in the region are expected to drive the depression drugs market in North America. Asia Pacific is likely to be a highly lucrative region of the global depression drugs market during the forecast period.
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Depression Drugs market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Depression Drugs market growth.
The global Depression Drugs market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
the global depression drugs market include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Allergan, Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Abbott, Pfizer, and GlaxoSmithKline.
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
Depression Drugs Market: Segmentation
- Depression Drugs Market, by Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- Atypical Antidepressants
- Tricyclic Antidepressants
- Others (CNS stimulants, monoamine oxidase inhibitors, etc.)
- Depression Drugs Market, by Disease Type
- Major Depressive Disorder
- Schizophrenia and Bipolar I Disorder
- Obsessive-Compulsive Disorders (OCD)
- Anxiety Disorder
- Others (ADHD, SSRI-induced disorder, etc.)
- Depression Drugs Market, by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
- North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Rest of EU
- Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Rest of APAC
- Central & South America
- Brazil
- Argentina
- Rest of Central & South America
- Middle East and Africa
- UAE
- Saudi Arabia
- Rest of MEA
Request Customization
Get a Sample
Get a Sample
Request Customization